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shown in previous studies, immunoglobulin antigenecity between different species does not appear to be a problem, 10, 11, 13 and furthermore both agents have the same chemical structure as the Fab portion of immunoglobulin.
Tissue Processing
Mice were killed by bleeding after puncturing the right ventricle. The blood was collected and allowed to clot. After the serum was separated, lipid profiles were analyzed. The vasculature was perfused with sterile phosphatebuffered saline. The root of the aorta was dissected under a macroscope and frozen in OCT embedding medium for serial cryosectioning covering 1.0 mm of the root. The first section was harvested when the first cusp became visible in the lumen of the aorta. Four sections of 10 m thickness were harvested per slide, and thus 20 slides per mouse were prepared. All sections were immersed for 2 min in 60% isopropanol, stained for 15 min in a saturated oil red-O solution at 37°C, counterstained with hematoxylin, and then mounted under coverslips with glycerol gelatin. 13, 14 
Quantitative Assessment of the Atherosclerotic Lesions
The oil red-O-stained sections were analyzed at a magnification of ×10, as previously described. 13, 14 The image was captured directly from the RGB camera attached to a light microscope and displayed on a microcomputer to quantify the cross-sectional surface area of the lesion and the crosssectional surface area of the vessel. The fractional area of the lesion was calculated by dividing the whole vessel area, including the lumen, intima, media and adventitia, as previously described. For each animal, 20 sections (ie, every 4th section) were examined, and the mean fractional area was calculated. 13, 15 
Immunohistochemistry
Aortic root cryosections from mice treated with immunoglobulin, F(ab')2 fragments, or HSA were processed for immunohistochemistry as described previously. 11, 12 In brief, anti-macrophage (anti-Mø, M3/84, 1:400, PharMingen, San Diego, CA, USA), anti-CD4 (GK1.5, 1:50, PharMingen), anti-CD8 (53-6.7, 1:50, PharMingen), and anti-I-A b (25-9-17, 1:25, PharMingen) antibodies were applied to acetonefixed cryosections. After being washed, the sections were then exposed to a second antibody (horseradish peroxidaseconjugated antibodies), and the antibody binding was visualized with diaminobenzidine. Sections were counterstained with 1% methyl green. The percentage of positively stained cells per cells infiltrating the lesions was calculated for each antibody, as previously described 13, 14 (ie, lesions of the aortic root were analyzed). Data were obtained by dividing the number of positively stained cells by all methyl green-stained cells inside the internal elastic lamina. Three to 5 random microscopic fields were analyzed at ×200.
Serum Lipid Measurement
Serum was separated by centrifugation and stored at -80°C. Serum total cholesterol and triglyceride levels were measured with assay kits (Wako) according to the manufacturer's instructions.
Statistical Analysis
Values were expressed as means ± SD. Statistical analysis of the data was determined by one-way ANOVA, followed by the Fisher protected least-significant-difference test. A value of p<0.05 was considered statistically significant.
Results

Effects of Immunoglobulin
Physiological Parameters As shown in Table 1 , treatment with the immunoglobulin preparations did not signifi- Effects of immunoglobulin and F(ab')2 fragments on atherosclerotic lesions. The lesions in the immunoglobulin-treated mice were smaller and covered a smaller fraction of the inner circumference of the aortic root than those in the control mice (arrows). However, the lesions in the F(ab')2 fragment-treated mice (arrows) were almost the same as those of the control mice (×40). HSA, human serum albumin.
cantly modify the serum lipid profiles, nor did it have an affect on body weight. Fatty Streak Formation Controls developed extensive lesions in the root of the aorta. Fatty streak lesions were suppressed by intact immunoglobulin administration, but not by F(ab')2 fragments (Fig 1) . In mice treated with intact immunoglobulin, the fractional area of the lesion was significantly reduced ( Table 2) .
Expression of Inflammatory Cells Macrophage and CD4 + cell accumulation in the fatty streak lesions was suppressed in the mice that received intact immunoglobulin but not in those receiving F(ab')2 fragments (Table 3, Fig 2) .
Discussion
This study clearly demonstrated that immunoglobulin treatment, even when initiated at a later stage of an experimental model of atherosclerosis, suppresses the development of the lesions associated with reduced expression of immune-activated cells in fatty streak plaques.
Intravenous immunoglobulin has been used to treat primary and secondary antibody deficiency for more than 25 years. 8, 9 It is a safe preparation with no long-term side effects. The therapy was first demonstrated to be effective for an autoimmune disorder (idiopathic thrombocytopenic purpura) 8 and since then, it has been established as effective in the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki's syndrome, and in the prevention of graft-vs-host disease in recipients of allogenic bone marrow transplants. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Benefits have been reported for many other autoimmune and systemic inflammatory conditions, but controlled trials are often lacking.
The mode of action of immunoglobulin is complex, involving modulation of the expression and function of Fc receptors, interference with the activation of complement and the cytokine network, provision of anti-idiotype antibodies, and effects on the activation, differentiation, and effector functions of T cells and B cells. 8, 9 At present, atherosclerosis is considered to be the result of generalized inflammation associated with immune activation. [1] [2] [3] We have already reported that immunoglobulin administration, beginning simultaneously with development of the disease, suppressed the lesions in experimental atherosclerosis via the actions of the Fc portion. 13 In the clinical setting, however, the disease is subclinical; that is, most patients with atherosclerosis have small or moderate lesions when they begin treatment. Accordingly, in the current study, our aim was to clarify the effects of immunoglobulin in apo E-deficient mice that already had atherosclerotic lesions. Our results showed that immunoglobulin treatment at a subsequent stage of atherosclerosis suppressed the further development of lesions associated with the reduced expression of macrophage and CD4 + cells in the fatty streak plaque.
Some of the beneficial effects of immunoglobulin therapy in autoimmune and immune-mediated disorders have been attributed to the Fc portion of the drug. 10, 11, 13, 16 Indeed, from our data, treatment with the intact type, but not with F(ab')2 fragments, significantly suppressed the severity of atherosclerotic lesions associated with reduced expression of macrophages or CD4 + cells. Recent studies suggest that one mode of action of immunoglobulin is via Fc receptor IIB, an inhibitory receptor, and that a large dose of immunoglobulin increases the expression this receptor. 16 Accordingly, it may be that plaque is stabilized by this inhibitory receptor. To date, there are no immunomodulating agents available for the prevention of atherosclerosis in the clinical setting, 17, 18 even though immune abnormalities are postulated as part of the disease's pathogenesis. Although there are some difficulties in the practical application of this therapy, exploration of the efficacy of this agent in human atherosclerosis appears warranted.
In conclusion, immunoglobulin administration, even at a subsequent stage in the progression of the disease, has the potential to reduce the development of lesions associated with the reduced expression of immune-activated cells in fatty streak plaques.
